As of 2025-09-19, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (18.36) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.54 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -343.5%.
The range of the Relative Valuation is (17.87) - (18.94) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.4x - 18.4x | 17.8x |
| Forward P/E multiples | 17.4x - 19.3x | 18.0x |
| Fair Price | (17.87) - (18.94) | (18.36) |
| Upside | -337.0% - -351.2% | -343.5% |
| Date | P/E |
| 2025-09-17 | -7.13 |
| 2025-09-16 | -7.11 |
| 2025-09-15 | -6.88 |
| 2025-09-12 | -6.81 |
| 2025-09-11 | -6.81 |
| 2025-09-10 | -6.81 |
| 2025-09-09 | -7.05 |
| 2025-09-08 | -7.08 |
| 2025-09-05 | -7.46 |
| 2025-09-04 | -6.70 |
| 2025-09-03 | -6.35 |
| 2025-09-02 | -6.24 |
| 2025-08-29 | -6.31 |
| 2025-08-28 | -6.47 |
| 2025-08-27 | -6.45 |
| 2025-08-26 | -6.35 |
| 2025-08-25 | -6.24 |
| 2025-08-22 | -6.70 |
| 2025-08-21 | -6.35 |
| 2025-08-20 | -6.40 |
| 2025-08-19 | -6.44 |
| 2025-08-18 | -6.46 |
| 2025-08-15 | -6.64 |
| 2025-08-14 | -6.43 |
| 2025-08-13 | -6.67 |
| 2025-08-12 | -6.37 |
| 2025-08-11 | -6.17 |
| 2025-08-08 | -6.32 |
| 2025-08-07 | -6.63 |
| 2025-08-06 | -6.76 |
| 2025-08-05 | -6.70 |
| 2025-08-04 | -6.78 |
| 2025-08-01 | -6.65 |
| 2025-07-31 | -6.55 |
| 2025-07-30 | -6.72 |
| 2025-07-29 | -7.39 |
| 2025-07-28 | -7.60 |
| 2025-07-25 | -7.60 |
| 2025-07-24 | -7.61 |
| 2025-07-23 | -7.70 |
| 2025-07-22 | -6.86 |
| 2025-07-21 | -6.91 |
| 2025-07-18 | -7.45 |
| 2025-07-17 | -7.73 |
| 2025-07-16 | -7.67 |
| 2025-07-15 | -7.63 |
| 2025-07-14 | -7.69 |
| 2025-07-11 | -7.62 |
| 2025-07-10 | -7.80 |
| 2025-07-09 | -7.70 |